Blog

After four years of declining sales, The Buckle (NYSE: BKE) is on pace to finish its fiscal year with a revenue increase.

As the retail apocalypse expanded and swallowed revenue from

Sasol (NYSE: SSL) has been hurt by cost overruns and other problems at its massive Lake Charles, Louisiana chemical project, resulting in a management shakeup last year. But when it resumes

Last September, Zillow Group (NASDAQ: Z)(NASDAQ: ZG) announced that its iBuying business, Zillow Offers, was partnering with a group of home builders in select Zillow Offers markets to help simplify

Dividend stocks are a powerful way to boost the return on capital of any portfolio. That being said, it can be a chore to unearth income stocks worth owning for long periods of time. The fundamental

Stratasys (NASDAQ: SSYS) hasn't yet announced a date for the release of its fourth-quarter and full-year 2019 results, but investors can probably expect them to come out by early March.

This will be

Shares of clinical-stage vaccine developer Novavax (NASDAQ: NVAX) are on the rise today, up 10.7% as of 10:22 a.m. EST. This double-digit move higher appears to be the result of two unrelated

Small-cap bank stocks can be great investments. They can grow fast. They are very safe these days (there were very few bank failures in 2018 and 2019). And many small-cap bank stocks come with

The rise of the cloud has been one of the best investment themes of the last decade. What started out as little more than a buzzword among techies has grown into a massive industry, hauling in

Shares of Teradyne (NASDAQ: TER) rose as much as 10.8% early Thursday morning, boosted by a strong fourth-quarter earnings report. The maker of automatic testing tools used by manufacturers of

After market close on Tuesday, Irish drug company Horizon Therapeutics (NASDAQ: HZNP) received a nice surprise from the Food and Drug Administration (FDA). The company's drug Tepezza was approved

Investors weren't impressed with Netflix (NASDAQ: NFLX) following the announcement of its fourth-quarter results, sending the shares nearly 4% lower on Wednesday. The biggest sticking point was that

Pfizer (NYSE: PFE) will provide patients of Roman, a men's health subsidiary of the privately held digital health company Ro, with the only Pfizer-authorized generic version of Viagra, a blockbuster

Uber (NYSE: UBER) Eats is shrinking its footprint once again. Following the company's decision to back out of food delivery in South Korea in October, the ride-hailing giant is selling its Uber Eats

Biotech stocks are well-known for their eye-popping valuations. What causal investors may miss, though, is that classic valuation metrics -- such as the price-to-earnings ratio -- rarely capture the

The past year has been a busy one for shareholders of eBay (NASDAQ: EBAY). The online marketplace's growth rebound fizzled in 2019, with sales falling under the weight of intense competition and

The stock market was kind to investors in 2019, with the Dow Jones Industrials rising 22% and the broader-based S&P 500 coming in with a 29% rise even before adding in dividends. You won't see those

3D Systems (NYSE: DDD) hasn't yet announced a date for the release of its fourth-quarter and full-year 2019 results, but it should be during the last week in February, or perhaps one of the first

The U.S. Army has pulled the plug on its planned $45 billion competition to replace its mainstay Bradley Fighting Vehicle, deciding instead to go back to the drawing board and rework what it is

The idea of Netflix (NASDAQ: NFLX) someday adding advertising to its service remains a perennial topic among investors and analysts. Needham analyst Laura Martin recently renewed her call that

One of the toughest aspects of retirement planning is that nobody has all the right answers. There's not necessarily a correct answer as to exactly how much the average person should save, or what

Shares of both Exact Sciences (NASDAQ: EXAS) and Qiagen (NYSE: QGEN) have undergone a rocky ride over the past few months. What caused this? For Qiagen, the stock dropped below $30 in October

Intercept Pharmaceuticals (NASDAQ: ICPT) is in the enviable position of many biotech companies. It boasts a marketed drug on pace to deliver more than $200 million in sales for 2019 and is

Roku (NASDAQ: ROKU) highlighted international markets as one of its big areas of investment for 2019. Management warned, however, that the investments in those markets won't show up in its results

Investors can't discount the possibility that the field of cellular medicine is a little overhyped right now, but the potential is huge.

Researchers are toiling away at the bench and in the clinic

Merck's (NYSE: MRK) cancer immunology drug, Keytruda, is already one of the best-selling drugs in the world and is well on track to becoming the No. 1 drug by revenue within the next few years